Shanghai and Shenzhen Stock Exchanges: Cofoe Medical Technology (01187) and WELLCELL HOLD (02477) will be included in the Stock Connect program.
Transfer the securities of Ke Fu Medical and Jingwei Tiandi into the list of securities eligible for Hong Kong Stock Connect, effective from May 6th, 2026.
The Shanghai and Shenzhen Stock Exchanges respectively announced that, according to the relevant provisions of the "Implementation Measures of Shanghai Stock Exchange Shanghai-Hong Kong Stock Connect Business" and the "Implementation Measures of Shenzhen Stock Exchange Shenzhen-Hong Kong Stock Connect Business", Cofoe Medical Technology (01187) has not applied the price stabilization period mechanism in its listing on the Hong Kong Stock Exchange and the corresponding A-share listing has reached 10 trading days, while WELLCELL HOLD (02477) has started trading and splitting its shares in parallel. Therefore, Cofoe Medical Technology and WELLCELL HOLD will be included in the list of stocks eligible for trading under the Hong Kong stock connect program, effective from May 6, 2026.
Related Articles
HK Stock Market Move | Hongteng Precision (06088) continues to rise by over 6%. In April, Hon Hai's revenue hit a historical high for the same period, driven by the strong momentum of its AI cloud products.
New Stock Preview | Mike Energy is Breaking through in Hong Kong Stocks: The Industry is Thriving, but what About its Own "Achilles' Heel"?
HK Stock Market Move | AKESO (09926) rose more than 5% in early trading. Institutions are still optimistic about ivonescimab beating K medicine.
HK Stock Market Move | Hongteng Precision (06088) continues to rise by over 6%. In April, Hon Hai's revenue hit a historical high for the same period, driven by the strong momentum of its AI cloud products.
New Stock Preview | Mike Energy is Breaking through in Hong Kong Stocks: The Industry is Thriving, but what About its Own "Achilles' Heel"?
HK Stock Market Move | AKESO (09926) rose more than 5% in early trading. Institutions are still optimistic about ivonescimab beating K medicine.
